Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
暂无分享,去创建一个
B. Haffty | James B. Yu | M. Sayan | Shi-Yi Wang | S. Jhawar | Apar Gupta | Z. A. Yehia
[1] M. Krause,et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Solin,et al. De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Vicini,et al. Radiation Therapy without Endocrine Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. , 2019, International journal of radiation oncology, biology, physics.
[4] S. Nik-Zainal,et al. Ductal carcinoma in situ: to treat or not to treat, that is the question , 2019, British Journal of Cancer.
[5] B. McCormick. Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804 , 2018, International Journal of Radiation Oncology*Biology*Physics.
[6] Zong-fang Li,et al. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis , 2018, Pathology & Oncology Research.
[7] S. Narod,et al. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy , 2018, JAMA network open.
[8] Jean L Wright,et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. , 2018, Practical radiation oncology.
[9] R. Jagsi,et al. Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. , 2018, International journal of radiation oncology, biology, physics.
[10] E. Rakovitch,et al. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy. , 2018, Breast.
[11] S. Shirvani,et al. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer , 2017, Journal of the National Cancer Institute.
[12] S. Giordano,et al. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ , 2017, Cancer.
[13] J. Bergh,et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Clemons,et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Butow,et al. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions? , 2017, Breast Cancer.
[16] A. Recht,et al. Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[18] F. Vicini,et al. Management of Ductal Carcinoma In Situ of the Breast: A Review. , 2016, JAMA oncology.
[19] T. Julian,et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.
[20] J. Cuzick,et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial , 2016, The Lancet.
[21] D. Buist,et al. Tamoxifen Initiation After Ductal Carcinoma In Situ , 2016, The oncologist.
[22] M. Rendi,et al. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base , 2015, Annals of Surgical Oncology.
[23] E. Rakovitch,et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. , 2014, International journal of radiation oncology, biology, physics.
[24] J. Bruce,et al. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. , 2014, Breast.
[25] C. Gross,et al. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer. , 2014, Journal of the National Cancer Institute.
[26] V. Budach,et al. The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study , 2013, Cancer medicine.
[27] B. Czerniecki,et al. Factors Influencing Surgical and Adjuvant Therapy in Stage I Breast Cancer: A SEER 18 Database Analysis , 2013, Annals of Surgical Oncology.
[28] P. Hall,et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.
[29] E. Elkin,et al. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Ocaña,et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.
[31] R Peto,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[32] T. Julian,et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.
[33] Eric J Feuer,et al. Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.
[34] J. Cuzick,et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.
[35] R. Peto,et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.
[36] H. Nelson,et al. Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer , 2009, Annals of Internal Medicine.
[37] T. Delea,et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. , 2007, Clinical breast cancer.
[38] J. Blume,et al. Can differences in breast cancer utilities explain disparities in breast cancer care? , 2006, Journal of General Internal Medicine.
[39] D. Fryback,et al. Report of Nationally Representative Values for the Noninstitutionalized US Adult Population for 7 Health-Related Quality-of-Life Scores , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[40] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[41] F. Vicini,et al. Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. Hillner,et al. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. , 2005, International journal of radiation oncology, biology, physics.
[43] R. Jagsi,et al. The management of ductal carcinoma in situ in North America and Europe , 2004, Cancer.
[44] Ron Goeree,et al. Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[45] E. Emanuel,et al. Influence of age on Medicare expenditures and medical care in the last year of life. , 2001, JAMA.
[46] C. Nilsson,et al. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[47] J. Thigpen. Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24 , 2012 .
[48] J. Yarnold,et al. Ductal Carcinoma in Situ (DCIS) of the breast , 2012 .
[49] M. Lesperance,et al. Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ , 2011, Cancer.
[50] S. Schnitt,et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.